CDA-AMC recommends public reimbursement of LEQEMBI (lecanemab) for early Alzheimer’s disease Eisai Canada announced that Canada’s Drug Agency (CDA-AMC) has issued a positive recommendation...
Browsing Tag: Alzheimer's
CDA-AMC recommends public reimbursement of LEQEMBI (lecanemab) for early Alzheimer’s disease Eisai Canada announced that Canada’s Drug Agency (CDA-AMC) has issued a positive recommendation...